2 FTSE 100 growth giants that could help you retire early

These FTSE 100 (INDEXFTSE:UKX) growth stocks could be big winners, says G A Chester.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When you look at the history of the FTSE 100 over the long term, you’ll find lots of companies clustered around the average performance mark — but only a few really big winners and, of course, some big underperformers.

Today, I’m looking at two stocks that I believe have the credentials to deliver outsize returns for investors today. Indeed, I believe the growth prospects of these two firms are so strong that they could even help you retire early.

World leader

Last year was transformative for drugmaker Shire (LSE: SHP). Its $32bn merger with US firm Baxalta created the world leader in rare diseases. Being the global number one in a large and expanding market gives Shire the potential to deliver superior returns for investors in the decades to come.

In its annual results, released in February, the company reported that the Baxalta integration is progressing ahead of schedule, with operating expense synergy initiatives bearing fruit earlier than expected and legacy Baxalta products transitioning quickly onto Shire’s commercial platform. I’m expected further positive news on the progress of the integration when the company announces its Q1 results next Tuesday.

In addition to the existing portfolio of drugs, Shire’s pipeline is now stronger and deeper than it’s ever been, making chief executive Flemming Ornskov “extremely optimistic” about the company’s long-term growth prospects. I believe the valuation at the current share price of 4,625p represents a great opportunity for investors to buy into these prospects.

Company guidance on diluted earnings per share (EPS) for 2017 is $4.87 to $5.07, compared with a pro forma $4.37 last year, giving growth of 11.4% to 16%. At current exchange rates, the EPS guidance equates to 380p to 396p, giving an undemanding price-to-earnings (P/E) ratio at the 388p mid-point of 11.9.

Pioneering powerhouse

Worldpay (LSE: WPG) is another stock I believe could deliver outsized returns. This card, online and contactless payments processor serves 400,000 merchants in 126 currencies across 146 countries, offering over 300 payment methods. It’s the number one processor in the UK (42% of all transactions), as well as one of the leading global operators.

The move from cash to electronic transactions is a great structural growth driver for Worldpay, but this pioneering company is also aiming to lead the way in expanding global reach, data analytics and optimisation, and the emerging field of integrated payments.

All of this adds up to a business that could deliver tremendous growth and returns for shareholders long into the future. In the shorter term, analysts have been regularly upgrading their earnings forecasts for 2017 and 2018. As things presently stand, with the shares at 302p, the P/E is 22.2, falling to 19.2.

I wouldn’t be surprised to see further earnings upgrades, bringing the P/Es down but the investment case doesn’t rest on that. I believe the shares are very buyable at their current level, based on what I see as the company’s terrific long-term growth prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Worldpay. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing For Beginners

The Barclays share price keeps surging! Was I wrong to sell the stock?

Jon Smith explains why the Barclays share price is still rising, even though he feels that further gains could be…

Read more »

Investing Articles

1 stock set to gatecrash the FTSE 100 in 2025!

Our writer considers a quality stock that's poised to join the FTSE 100 next year. Could there also be a…

Read more »

Businesswoman calculating finances in an office
Investing Articles

As earnings growth boosts the Imperial Brands share price, is it a top FTSE 100 dividend choice?

The Imperial Brands share price has come storming back as investors piled in for the big dividends. What's next, after…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
US Stock

Warren Buffett just bought and sold these stocks. Here’s why I don’t agree

Jon Smith takes a look at the recent regulatory filing for Berkshire Hathaway and Warren Buffett and comments on recent…

Read more »

US Stock

My favourite US growth stock’s up 33% this year. I think it’s just getting started

Edward Sheldon's taken a large position in this well-known S&P 500 growth stock. And so far, it’s working very well…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

The Diploma share price falls 7% as revenues and profits keep growing. Time to buy?

As Diploma continues its impressive growth, its share price is faltering. Stephen Wright takes a closer look at one of…

Read more »

Growth Shares

Directors at this FTSE 100 company just bought over £2m worth of shares

Shares in this FTSE 100 pharma company have plummeted in recent months. And company insiders are betting on a potential…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Down 24%! As the Glencore share price falls like snow, is it finally time to let it go?

Harvey Jones thought the Glencore share price was in bargain territory when he bought the FTSE 100 commodity giant last…

Read more »